By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



245 First Street - 18th Floor
Suite 1806
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-444-8416 Fax: 617- 444-8405

Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.

Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.

Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.

Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.

Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
59120 Loos
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001

Key Statistics

Ownership: Public

Web Site: GENFIT
Employees: 125 (Scientists: 100)
Symbol: ALGFT

Company News
GENFIT (ALGFT): Ordinary And Extraordinary Shareholders' Meeting Of June 16, 2017 - Availability Of Preparatory Documents 5/19/2017 10:05:39 AM
GENFIT (ALGFT) : Convening Notice To The Ordinary And Extraordinary Shareholders Meeting On June 16, 2017 5/15/2017 10:07:46 AM
GENFIT (ALGFT): First Patient Enrolled In A Phase II Trial Recruiting Adults With Primary Biliary Cholangitis (PBC), A Rare Liver Disease 5/5/2017 10:39:33 AM
GENFIT (ALGFT): First Patient Enrolled In A Phase II Trial Recruiting Adults With Primary Biliary Cholangitis (PBC), A Rare Liver Disease 5/5/2017 8:14:38 AM
GENFIT (ALGFT): Publication Of The 2016 Registration Document 5/1/2017 11:57:19 AM
GENFIT (ALGFT) : Q1 2017 FINANCIAL Information 4/24/2017 11:17:01 AM
Data To Be Presented At EASL 2017 Highlighting GENFIT (ALGFT)’s Latest Progress In NASH Biomarker Diagnostics, Identifying Novel Compounds With Potent Antifibrotic Properties, And Illustrating The Opportunities In Anti-NASH Drug Combinations 4/5/2017 11:40:54 AM
GENFIT (ALGFT) To Host A Series Of KOL Meetings In NASH 3/28/2017 10:43:38 AM
Rumor Alert: Novartis AG (NVS) In Talks to Buy NASH Biotech GENFIT (ALGFT) 3/3/2017 6:25:05 AM
GENFIT (ALGFT): The NASH Education Program – Inaugural Press Conference, Paris – March 9, 2017 2/14/2017 8:44:04 AM